Figure 8. Inhibition of PARG activity reduces both DNA-PKcs and tankyrase 1 protein levels. (A) Treatment with the PARG inhibitor ADP-HPD (10 hr) prevents removal of pADPr from PARP modified proteins and resulted in reduction of DNA-PKcs levels relative to the DMSO treated control. The combination treatment of both ADP-HPD and XAV939 (10 hr) resulted in reduction of DNA-PKcs, similar to XAV939 treatment alone (Figure